Enanta Pharmaceuticals (ENTA) News Today $6.84 +0.35 (+5.33%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Enanta Pharmaceuticals: Fiscal Q3 Earnings SnapshotAugust 11 at 10:38 PM | sfgate.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025August 11 at 4:02 PM | businesswire.comQ3 Earnings Estimate for ENTA Issued By HC WainwrightJuly 31, 2025 | marketbeat.comEnanta Pharmaceuticals' (ENTA) Buy Rating Reaffirmed at HC WainwrightJuly 28, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) Projected to Post Earnings on MondayJuly 28, 2025 | marketbeat.comOne Enanta Pharmaceuticals Insider Raised Their Stake In The Previous YearJuly 26, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by BrokeragesJuly 23, 2025 | marketbeat.comEnanta Pharmaceuticals to Participate in Baird’s Biotech Discovery SeriesJuly 16, 2025 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Baird's Biotech Discovery SeriesJuly 15, 2025 | businesswire.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 28, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (ENTA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Increased to Hold at Wall Street ZenJune 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Reduces Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)June 19, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by Wall Street Zen to "Sell"June 14, 2025 | marketbeat.comFDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)June 11, 2025 | finance.yahoo.comEnanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C VirusJune 11, 2025 | businesswire.comTwo Sigma Investments LP Sells 126,974 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)June 11, 2025 | marketbeat.comAmeriprise Financial Inc. Has $405,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)June 5, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by AnalystsJune 3, 2025 | marketbeat.comJMP Securities Issues Positive Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock PriceJune 3, 2025 | marketbeat.comTwo Sigma Advisers LP Cuts Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)June 2, 2025 | marketbeat.comMillennium Management LLC Acquires 165,692 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 30, 2025 | marketbeat.comEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 27, 2025 | finance.yahoo.comNorthern Trust Corp Has $2.23 Million Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 27, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the ...May 24, 2025 | finanznachrichten.deD. E. Shaw & Co. Inc. Has $2.42 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 23, 2025 | marketbeat.com331,900 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Acquired by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires 98,285 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 19, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 17, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 15, 2025 | uk.finance.yahoo.comEnanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to AnalystsMay 5, 2025 | insidermonkey.com1,038,000 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Purchased by RA Capital Management L.P.May 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Caligan Partners LPMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $492,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Has $938,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 30, 2025 | marketbeat.comMarshall Wace LLP Increases Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 26, 2025 | marketbeat.comFederated Hermes Inc. Trims Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 21, 2025 | marketbeat.comTrexquant Investment LP Acquires 67,040 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 14, 2025 | marketbeat.comPrudential Financial Inc. Lowers Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 13, 2025 | marketbeat.comEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025April 8, 2025 | businesswire.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from BrokeragesApril 6, 2025 | marketbeat.comEnanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to ImmunologyMarch 29, 2025 | investing.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average - Here's What HappenedMarch 26, 2025 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Decreases By 27.2%March 17, 2025 | marketbeat.comEnanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 17, 2025 | businesswire.comEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV SymposiumMarch 12, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by BrokeragesMarch 11, 2025 | marketbeat.com Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼0.630.75▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼52▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZVRA News Today PRME News Today REPL News Today EOLS News Today PHAT News Today KROS News Today RLAY News Today BCAX News Today TLRY News Today ORGO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredSell these stocks now—what to buy insteadSell these stocks now—Here’s what to buy instead Wall Street legend Marc Chaikin says you must know these 3...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTurn Trump's Market Boom into $5,917 Monthly ChecksHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access